In infants and young children, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is administered as a 4-dose series at 2, 4, 6 and 12 to 15 months of age.1*†‡
*The first dose may be given as early as 6 weeks of age.1
†The recommended dosing interval for the first, second and third doses is 4 to 8 weeks.1
‡The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.1
Model used for illustrative purposes only.
Helping to protect babies from invasive pneumococcal disease and acute otitis media1
PREVNAR includes both PREVNAR® (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and PREVNAR 13®*
*In the US, PCV7 was available from 2000 to 2010 and PCV13 has been available since 2010.
Offer resources that may help improve adherence to the CDC-recommended vaccine schedule
To stock Prevnar 13®, call
1-800-666-7248 or click here
PREVNAR 13® is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2022 Pfizer Inc.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?